Status:
COMPLETED
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \...
Detailed Description
This is interventional study and single arm study. N/A
Eligibility Criteria
Inclusion
- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.
- ER positive.
- The patient must be postmenopausal woman.
- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will necessarily precede and will be independent of the decision to enroll patients in the study).
Exclusion
- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin® treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.
- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin®).
Key Trial Info
Start Date :
February 9 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2018
Estimated Enrollment :
564 Patients enrolled
Trial Details
Trial ID
NCT01176916
Start Date
February 9 2011
End Date
November 30 2018
Last Update
October 27 2021
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, China, 233004
2
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
3
Second Affiliated hospital of Anhui Medical University
Hefei, Anhui, China, 230601
4
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016